Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan

Master et al. (2021) declared that the unproven stem cell intervention (SCI) industry is a global health problem. We fully agree with this opinion but would like to point out that there are financial risks. In this letter, we estimate the total refund amount paid by the government for cell-based int...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatta, Taichi, Ide, Kazuki, Fujita, Misao, Ikka, Tsunakuni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133642/
https://www.ncbi.nlm.nih.gov/pubmed/35452594
http://dx.doi.org/10.1016/j.stemcr.2022.03.015
_version_ 1784713616191127552
author Hatta, Taichi
Ide, Kazuki
Fujita, Misao
Ikka, Tsunakuni
author_facet Hatta, Taichi
Ide, Kazuki
Fujita, Misao
Ikka, Tsunakuni
author_sort Hatta, Taichi
collection PubMed
description Master et al. (2021) declared that the unproven stem cell intervention (SCI) industry is a global health problem. We fully agree with this opinion but would like to point out that there are financial risks. In this letter, we estimate the total refund amount paid by the government for cell-based interventions offered under private practice in Japan.
format Online
Article
Text
id pubmed-9133642
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91336422022-05-27 Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan Hatta, Taichi Ide, Kazuki Fujita, Misao Ikka, Tsunakuni Stem Cell Reports Letter Master et al. (2021) declared that the unproven stem cell intervention (SCI) industry is a global health problem. We fully agree with this opinion but would like to point out that there are financial risks. In this letter, we estimate the total refund amount paid by the government for cell-based interventions offered under private practice in Japan. Elsevier 2022-04-21 /pmc/articles/PMC9133642/ /pubmed/35452594 http://dx.doi.org/10.1016/j.stemcr.2022.03.015 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter
Hatta, Taichi
Ide, Kazuki
Fujita, Misao
Ikka, Tsunakuni
Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan
title Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan
title_full Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan
title_fullStr Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan
title_full_unstemmed Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan
title_short Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan
title_sort financial risks posed by unproven cell interventions: estimation of refunds from medical expense deductions in japan
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133642/
https://www.ncbi.nlm.nih.gov/pubmed/35452594
http://dx.doi.org/10.1016/j.stemcr.2022.03.015
work_keys_str_mv AT hattataichi financialrisksposedbyunprovencellinterventionsestimationofrefundsfrommedicalexpensedeductionsinjapan
AT idekazuki financialrisksposedbyunprovencellinterventionsestimationofrefundsfrommedicalexpensedeductionsinjapan
AT fujitamisao financialrisksposedbyunprovencellinterventionsestimationofrefundsfrommedicalexpensedeductionsinjapan
AT ikkatsunakuni financialrisksposedbyunprovencellinterventionsestimationofrefundsfrommedicalexpensedeductionsinjapan

Ejemplares similares